Cobra Venom Factor
Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.
Product Specifications
Citations | 27 |
---|---|
Description |
Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent. |
Storage | Store at -70°C or below. Minimize freeze/thaw cycles. |
Form |
Frozen liquid (Phosphate Buffered Saline, pH 7.2 ± 0.2) |
Concentration | 1.0-1.2 mg/mL |
Applications |
See citations and technical data sheet for application info. |
Ordering Information
Catalog Number | A600 |
---|---|
Catalog Number (CE) | N/A |
Size | 1.0 mg |
Price (USD) | $400.00 |
Price (EURO) | 355,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description |
Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent. |
---|---|
Size | 1.0 mg |
Storage |
Store at -70°C or below. Minimize freeze/thaw cycles. |
Form | Frozen liquid (Phosphate Buffered Saline, pH 7.2 ± 0.2) |
Concentration | 1.0-1.2 mg/mL |
Applications | See citations and technical data sheet for application info. |
Purity | ≥ 95% by SDS page |
Source |
Naja naja kaouthia (cobra) |
Activity | 8 units/mL to 20 units/mL for full complement conversion. |
Molecular Weight | N/A |
Background |
Cobra Venom Factor (CVF), sometimes referred to as C3b(Cobra), is the non-toxic, complement activating component of cobra venom. Like naturally occurring C3b, CVF forms a complex with complement components Factor B and Factor D. This CVFBbD convertase is capable of activating C3 in a wide variety of species via the alternative complement pathway. Unlike the naturally occurring convertase (C3bBbD), the C3b(Cobra)BbD convertase is Factor H resistant and is therefore not inactivated by Factor I or CR1. Given appropriate incubation time, CVF will convert nearly 100% of the C3 to C3 end products. Unlike CVF purified from the Naja naja haje species, CVF from Naja naja kaouthia activates the terminal pathway directly by forming a C5 convertase. This depletes C5 in a manner analogous to that described above for C3. Levels of iC3b, C3a, SC5b-9, C5a and the Factor B cleavage product Bb are all extremely high in CVF treated sera. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2012 | Complement Depletion Assay |
Baboon |
Protein Injection |
||
2016 | Complement Depletion Assay |
Baboon |
Protein Injection |
||
2020 | Complement Activation Assay |
Human |
Plasma |
||
2009 | Complement Activation Assay |
Human |
Plasma |
Gold Nanoparticles incubated |
|
Zwitterionic chitosan derivatives for pH-sensitive stealth coating |
2010 | Complement Activation Assay |
Human |
Plasma |
|
Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation |
2016 | Complement Activation Assay |
Human |
Serum |
|
2022 | Complement Depletion Assay |
Human |
Serum |
||
2016 | Complement Depletion Assay |
Human |
Serum |
||
Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3 |
2017 | Complement Depletion Assay |
Human |
Serum |
|
2021 | WB |
Human |
Purified protein |
||
2005 | Complement Depletion Assay |
Mouse |
Protein Injection |
||
2008 | Complement Depletion Assay |
Mouse |
Protein Injection |
||
2009 | Complement Depletion Assay |
Mouse |
Protein Injection |
||
2009 | Complement Depletion Assay |
Mouse |
Protein Injection |
||
2013 | Complement Depletion Assay |
Mouse |
Protein Injection |
||
Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release |
2013 | Complement Depletion Assay |
Mouse |
Protein Injection |
|
2014 | Complement Depletion Assay |
Mouse |
Protein Injection |
||
2014 | Complement Depletion Assay |
Mouse |
Protein Injection |
||
2015 | Complement Depletion Assay |
Mouse |
Protein Injection |
||
2017 | Complement Depletion Assay |
Mouse |
Protein Injection |
||
Complement Depletion Improves Human Red Blood Cell Reconstitution in Immunodeficient Mice |
2017 | Complement Depletion Assay |
Mouse |
Serum |
|
2013 | IF |
Mouse |
Ear dermis Tissue |
||
Treatment with Cobra Venom Factor Decreases Ischemic Tissue Damage in Mice |
2024 | Complement depletion assay |
Mouse |
Serum |
Tissue ischemia |
No expression of porcine endogenous retrovirus after pig to monkey xenotransplantation |
2014 | Complement Depletion Assay |
Porcine |
Protein Injection |
|
2015 | Complement Depletion Assay |
Rat |
Protein Injection |
||
2016 | Complement Depletion Assay |
Rat |
Protein Injection |
||
2016 | Complement Depletion Assay |
Rat |
Protein Injection |